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HE concept of induction therapy followed by
maintenance therapy has its origins in the treat-
ment of a number of infectious and neoplastic diseas-
es. Highly potent but toxic and inconvenient treat-
ment is given for several weeks or months to induce
a rapid therapeutic response. This period is followed
by several months of less intense therapy to consol-
idate the effect, reduce toxicity, and provide patients
with a well-deserved break. In some cancers, reser-
voirs of disease that are not accessible to systemic
therapy are treated in the interim. At the end of the
treatment many patients are cured, probably because
their immune systems are able to control any resid-
ual microbes or tumor cells. The approach has proved
effective for the treatment of tuberculosis and some
forms of cancer, particularly acute lymphoblastic
leukemia.
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It is small wonder that induction therapy followed
by maintenance therapy is an appealing strategy for
the antiretroviral treatment of human immunodefi-
ciency virus type 1 (HIV-1) infection. Emerging data
indicate that induction therapy with four or five
drugs results in more rapid suppression of HIV-1
replication than treatment with standard three-drug
regimens.
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 Hard-to-reach areas such as the central
nervous system, which act as reservoirs for the virus,
may be pharmacologically accessible to several anti-
retroviral drugs.
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 Less intense maintenance phases
may also be needed because of the toxicity of highly
active regimens that include HIV-1–protease inhib-
itors.
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 Increasingly, complex treatment regimens that
involve large numbers of pills, dietary restrictions,
and numerous drug interactions are problematic, at
least in the long term, for many patients.
Two studies in this issue of the 
 
Journal
 
 — one by
the Trilège Study team
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 and one by the AIDS Clinical
Trials Group Study 343 (ACTG 343) team
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 — and
the recent Amsterdam Duration of Antiretroviral
Medication (ADAM) study
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 reflect the remarkably
consistent outcomes of randomized, controlled trials
that assess the relative merits of antiretroviral induc-
tion therapy followed by maintenance therapy. The
studies enrolled a total of 949 patients with HIV-1
infection. The Trilège and ADAM studies recruited
patients who had not previously received antiretrovi-
ral therapy, whereas in the ACTG 343 study patients
were eligible even if they had been treated previously
with zidovudine. From enrollment, patients received
a three-drug regimen in the Trilège and ACTG 343
studies and a four-drug regimen in the ADAM study
T
 
for induction phases of 12, 24, and 26 weeks, respec-
tively. Each regimen included combinations of nucle-
oside-analogue HIV-1 reverse-transcriptase inhibitors
and HIV-1–protease inhibitors. At the completion of
the induction phase, patients were eligible for ran-
dom assignment to a number of maintenance regi-
mens if they were in remission (defined as a plasma
HIV RNA level below a predefined value). In each
study, the primary end point was defined as an in-
crease in plasma HIV RNA levels above a preset value.
In all three studies, significantly fewer patients who
continued to receive the induction regimens, rather
than a less intense maintenance regimen, reached the
end point.
The failure to maintain the response to antiretro-
viral therapy should prompt us to ask what the dif-
ference is between HIV-1 infection and the other
diseases for which this strategy has been successful.
The end point of cure, which the sequence of induc-
tion therapy followed by maintenance therapy is mar-
velously successful in achieving in tuberculosis and
some forms of cancer, has proved very elusive in
HIV infection. Two recent observations shed some
light on the reasons for this divergence. Seemingly
latent HIV-1 that is nonetheless able to replicate has
been found in long-lived CD4 cells.
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 In addition,
specific immunity, as measured by the proliferative
responses of CD4 helper T-cells to HIV-1 antigens,
does not appear to be preserved by antiretroviral
therapy unless the treatment is given during primary
infection or very early in the course of the disease.
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Consequently, for the moment, treatment must be
seen as a lifelong undertaking, since the immune sys-
tem is not able to clear residual disease. What can we
learn from the results of these three evidence-based
studies, which have examined a plausible therapeutic
strategy for HIV-1 infection?
First, these three studies were terminated 11 to 13
months after enrollment began. The decision to stop
the studies was based on virologically defined treat-
ment failures in 119 of 637 randomized patients (19
percent). Nevertheless, in the majority of patients
who received less intense regimens, viral replication
remained suppressed, suggesting that there are pa-
tients for whom this strategy is useful, as previously
proposed for a regimen containing a non-nucleoside
HIV-1 reverse-transcriptase inhibitor.
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 Whether such
patients are likely to relapse in the longer term is un-
clear. If they do not relapse, then they may have
more options for future treatment than patients who
are treated with more intensive therapy. Given the
limited follow-up in these studies, it would be pre-
mature to stop investigating the efficacy of induction
therapy followed by maintenance therapy for HIV-1
infection, especially in the light of new data showing
that the duration of remission is related to the
length of induction therapy and the potency of the
therapeutic regimen.
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Second, the observation in the ACTG 343 study
that the size of the increases in the CD4 cell count
during induction therapy was inversely correlated with
the probability of subsequent maintenance of remis-
sion led the authors to invoke a predator–prey hy-
pothesis to explain this apparent paradox. According
to this hypothesis, increasing the number of “prey”
(CD4 cells) would permit an increase in the number
of “predators” (HIV virus). This observation was
not confirmed in the Trilège or ADAM study, which
enrolled patients who had not previously received
antiretroviral therapy.
Another interpretation is that this correlation re-
sulted from the inclusion of patients (43 percent)
with prior zidovudine treatment (median, 90 weeks).
The overwhelming majority (94 percent) of patients
who were defined as having treatment failure and who
had large increases in the CD4 cell count during the
induction phase (>150 cells per cubic milliliter) re-
ceived maintenance regimens of indinavir monother-
apy or a combination of zidovudine and lamivudine.
Furthermore, the study clearly identifies both zido-
vudine resistance and prior zidovudine use as associ-
ated with subsequent failure. In this study, as in a
previous study of this regimen,
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 patients who had
received prior treatment with zidovudine had good
increases in CD4 cell counts during induction ther-
apy with lamivudine and indinavir. However, these
patients may do particularly badly during maintenance
therapy with regimens that are essentially mono-
therapy. Therefore, the apparent paradox may have
arisen because of the inclusion of previously treated
patients who harbored zidovudine-resistant HIV-1.
Nevertheless, it remains unclear why patients with
small increases in the CD4 cell count during induc-
tion therapy had higher rates of sustained remission
than those with larger increases in the CD4 cell
count. An analysis of the relation between changes
in CD4 cell counts during the induction phase and
base-line HIV-1 resistance to zidovudine could help
delineate this intriguing observation.
There may well be merit in modeling the inter-
action between HIV-1 and CD4 cells on a preda-
tor–prey system. Such a model proposes that in the
absence of effective antiretroviral therapy, HIV-1 rep-
lication will be enhanced after an increase in the
CD4 cell count. Certainly, the evaluation of thera-
pies that limit the activation or proliferation of
T cells is warranted in HIV-1 infection, and in this
respect there are some encouraging preliminary data
on hydroxyurea.
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 Immunotherapy with interleukin-
2, which selectively induces substantial CD4 cell
proliferation, is also known to generate transient
increases in plasma HIV-1 RNA. In a predator–prey
system, this effect would be predicted to result in
substantial increases in plasma HIV-1 RNA levels.
However, long-term evaluation of patients who
received interleukin-2 in addition to antiretroviral
therapy reveals that there was a small reduction in
plasma HIV-1 RNA levels over a period of 2
 
1
 
⁄
 
2
 
years.
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 It would appear either that the predator–
prey concept is wrong or that interleukin-2 has po-
tent antiretroviral activity in addition to its immuno-
modulatory activity.
Third, the fact that these studies have been con-
ducted is tacit acknowledgment of the difficulties
associated with current approaches to antiretroviral
therapy in clinical practice, notwithstanding the opin-
ion of consensus panels that recommend guidelines
for treatment.
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 Of the patients enrolled in the
Trilège, ACTG 343, and ADAM studies, some 34
percent were not randomly assigned to maintenance
therapy because they had an incomplete virologic re-
sponse (14 percent), had an adverse event or with-
drew consent (14 percent), or did not complete the
induction phase (6 percent).
We must think hard about the implications and
practicalities of a medical strategy based on aggres-
sive early intervention with lifelong, complex regi-
mens of antiretroviral therapy to preserve immuno-
competence after the suppression of a cytopathic
virus. If we could guarantee that this approach pre-
served subsequent options for treatment, did not
lead to cross-resistance, and worked for everybody
without serious complications, there would be no
debate. However, despite the remarkable reductions
in HIV-1–associated morbidity and mortality,
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 we
know these conditions are not met. We seem fixated
on pursuing the Holy Grail of preserving HIV-1–
specific and general immunity with the use of a sin-
gle strategy. Such a goal dismisses evidence that this
strategy is probably achievable, if at all, only through
the use of antiretroviral treatment during and up to
several months after primary HIV infection.
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We know that potent antiretroviral therapy works
well in patients with symptomatic HIV-1 infection.
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Relying on the redundancy of the immune system,
we successfully treat cancer, rejection of tissue and
organ transplants, and serious autoimmune disorders
with radiation therapy and antirejection and immu-
nosuppressive drugs. In these situations, the end re-
sult with respect to the immune system is qualita-
tively similar to that obtained with antiretroviral
treatment of HIV-1 infection.
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 Yet, given the current
limitations of antiretroviral therapy, investigators seem
unprepared to look beyond the guidelines and rise
to the challenge of comparing strategies of early, po-
tent antiretroviral therapy with deferred therapy for
HIV-1 infection. We believe that the Trilège, ACTG
343, and ADAM studies provide further impetus to
meet these challenges.
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